ReviewJournal of translational medicine2025
The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy.
Review in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Progress in biomedical engineering (Bristol, England) · 2026Review
- Specific PET Imaging for Precision Management of Lung Cancer: Advances, Clinical Translation and Future Directions.Chemical & biomedical imaging · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the context of cancer immunotherapy, assessing treatment response and predicting survival outcomes remain major challenges. Granzyme B (GZMB), released by cytotoxic T cells, represents the terminal effector event of activated antitumor immunity, thereby providing a robust rationale for GZMB-targeted positron emission tomography (GZMB PET) imaging as a noninvasive, real-time, and dynamic approach to monitoring immune activity within the tumor microenvironment. This review aims to 1) outline the molecular and immunological mechanisms of GZMB in antitumor immunity; 2) critically appraise the clinical value of GZMB PET beyond short-term response prediction; and 3) compare GZMB PET with existing imaging and biomarker‑based strategies, delineating its advantages, limitations, and translational prospects to inform future research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.